Global Combined Hormonal Contraceptives Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Combined Hormonal Contraceptives Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Combined hormonal contraceptives are used to prevent pregnancies. They are also used in the treatment of acne vulgaris, endometriosis, polycystic ovarian syndrome, and irregular menstrual flow by blocking ovulation. These products are widely used by women of aged between 15 and 49 years.
Combined Hormonal Contraceptives report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Combined Hormonal Contraceptives market is projected to reach US$ 22360 million in 2034, increasing from US$ 17780 million in 2022, with the CAGR of 3.3% during the period of 2024 to 2034. Demand from Hospital Pharmacy and Retail Pharmacy are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Combined Hormonal Contraceptives industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Combined Hormonal Contraceptives key manufacturers include Actavis, Agile Therapeutics, Allergan, Bayer, Teva Pharmaceutical Industries, ANI Pharmaceuticals, Ortho-McNeil-Janssen Pharmaceuticals, Noven Pharmaceuticals and Johnson & Johnson, etc. Actavis, Agile Therapeutics, Allergan are top 3 players and held % sales share in total in 2022.
Combined Hormonal Contraceptives can be divided into 15-24 years, 25-34 years, 35-44 years and Above 44 years, etc. 15-24 years is the mainstream product in the market, accounting for % sales share globally in 2022.
Combined Hormonal Contraceptives is widely used in various fields, such as Hospital Pharmacy, Retail Pharmacy and Online Pharmacy,, etc. Hospital Pharmacy provides greatest supports to the Combined Hormonal Contraceptives industry development. In 2022, global % sales of Combined Hormonal Contraceptives went into Hospital Pharmacy filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Combined Hormonal Contraceptives market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Actavis
Agile Therapeutics
Allergan
Bayer
Teva Pharmaceutical Industries
ANI Pharmaceuticals
Ortho-McNeil-Janssen Pharmaceuticals
Noven Pharmaceuticals
Johnson & Johnson
Mylan
Segment by Type
15-24 years
25-34 years
35-44 years
Above 44 years
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Combined Hormonal Contraceptives market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Combined Hormonal Contraceptives, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Combined Hormonal Contraceptives industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Combined Hormonal Contraceptives in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Combined Hormonal Contraceptives introduction, etc. Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Combined Hormonal Contraceptives market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Combined Hormonal Contraceptives report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Combined Hormonal Contraceptives market is projected to reach US$ 22360 million in 2034, increasing from US$ 17780 million in 2022, with the CAGR of 3.3% during the period of 2024 to 2034. Demand from Hospital Pharmacy and Retail Pharmacy are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Combined Hormonal Contraceptives industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Combined Hormonal Contraceptives key manufacturers include Actavis, Agile Therapeutics, Allergan, Bayer, Teva Pharmaceutical Industries, ANI Pharmaceuticals, Ortho-McNeil-Janssen Pharmaceuticals, Noven Pharmaceuticals and Johnson & Johnson, etc. Actavis, Agile Therapeutics, Allergan are top 3 players and held % sales share in total in 2022.
Combined Hormonal Contraceptives can be divided into 15-24 years, 25-34 years, 35-44 years and Above 44 years, etc. 15-24 years is the mainstream product in the market, accounting for % sales share globally in 2022.
Combined Hormonal Contraceptives is widely used in various fields, such as Hospital Pharmacy, Retail Pharmacy and Online Pharmacy,, etc. Hospital Pharmacy provides greatest supports to the Combined Hormonal Contraceptives industry development. In 2022, global % sales of Combined Hormonal Contraceptives went into Hospital Pharmacy filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Combined Hormonal Contraceptives market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Actavis
Agile Therapeutics
Allergan
Bayer
Teva Pharmaceutical Industries
ANI Pharmaceuticals
Ortho-McNeil-Janssen Pharmaceuticals
Noven Pharmaceuticals
Johnson & Johnson
Mylan
Segment by Type
15-24 years
25-34 years
35-44 years
Above 44 years
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Combined Hormonal Contraceptives market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Combined Hormonal Contraceptives, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Combined Hormonal Contraceptives industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Combined Hormonal Contraceptives in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Combined Hormonal Contraceptives introduction, etc. Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Combined Hormonal Contraceptives market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.